Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma LtdfiledCriticalTeijin Pharma Ltd
Publication of AR101362A1publicationCriticalpatent/AR101362A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporcionan: ácido 4-metil-2-[4-(2-metilpropoxi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-1,3-tiazol-5-carboxílico, una sal de sodio del mismo y cristales de estos, útiles como agente terapéutico y agente profiláctico para la gota, hiperuricemia y otras, y un método para producirlos. Reivindicación 1: Un cristal de ácido 4-metil-2-[4-(2-metilpropoxi)-3-(1H-1,2,3,4-tetrazol-1il)fenil]-1,3-tiazol-5-carboxílico.They are provided: 4-methyl-2- [4- (2-methylpropoxy) -3- (1H-1,2,3,4-tetrazol-1-yl) phenyl] -1,3-thiazol-5-carboxylic acid , a sodium salt thereof and crystals thereof, useful as a therapeutic agent and prophylactic agent for gout, hyperuricemia and others, and a method of producing them. Claim 1: A crystal of 4-methyl-2- [4- (2-methylpropoxy) -3- (1H-1,2,3,4-tetrazol-1yl) phenyl] -1,3-thiazol-5- acid carboxylic.
ARP150102421A2014-07-302015-07-29
DERIVED FROM AZOL BENCENO AND CRYSTAL FORM OF THE SAME
AR101362A1
(en)
(r) and (s) enantiomer of n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-carboxamide as irak4 inhibitors for treating cancer and inflammatory diseases
CRYSTAL FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY- PYRIDIN-4- YL)-[1,2,4]OXADIAZOL-3- YL]-2- ETHYL- 6-METHYL- PHENOXY}-PROPANE-1,2-DIOL